---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-030822"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:52:44.358801+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics Q2 net loss narrows to $7.4M; FDA grants RMAT for OPGx-LCA5

## Summary
- Net loss $7.4M ($0.12/share) vs $7.8M ($0.30) in Q2 2024; revenue $2.9M from Viatris collaboration.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 gene therapy.
- Positive 12-month adult and early pediatric data for OPGx-LCA5; 3-month pediatric data due Q3 2025.
- Phentolamine Phase 3 VEGA-3 (presbyopia) and LYNX-2 met primary endpoints; sNDA submission planned H2 2025.
- Cash $32.4M expected to fund operations into H2 2026; up to $3.6M non-dilutive funding secured for RDH12 and MERTK programs.

## SEC filing metadata
- accession: 0001140361-25-030822
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/0001140361-25-030822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/ef20053851_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-030822
- JSON: https://secwatch.observer/filing/0001140361-25-030822.json
- Plain text: https://secwatch.observer/filing/0001140361-25-030822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.